U.S. markets open in 4 hours 7 minutes

Arena Pharmaceuticals, Inc. (ARNA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
71.46-2.11 (-2.87%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close73.57
Open73.75
Bid70.30 x 1800
Ask73.06 x 900
Day's Range71.01 - 74.42
52 Week Range32.95 - 90.19
Volume511,320
Avg. Volume539,942
Market Cap4.312B
Beta (5Y Monthly)0.73
PE Ratio (TTM)N/A
EPS (TTM)-7.39
Earnings DateMay 05, 2021 - May 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est94.93
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Arena (ARNA) Tumbles as Mid-Stage Gastrointestinal Study Fails
    Zacks

    Arena (ARNA) Tumbles as Mid-Stage Gastrointestinal Study Fails

    Arena's (ARNA) mid-stage study evaluating olorinab in patients with abdominal pain due to irritable bowel syndrome fails to meet primary endpoint.

  • Benzinga

    Return On Capital Employed Overview: Arena Pharmaceuticals

    During Q4, Arena Pharmaceuticals's (NASDAQ:ARNA) reported sales totaled $37.00 thousand. Despite a 23.83% in earnings, the company posted a loss of $122.35 million. Arena Pharmaceuticals collected $20.00 thousand in revenue during Q3, but reported earnings showed a $98.80 million loss. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q4, Arena Pharmaceuticals posted an ROCE of -0.11%. Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future. View more earnings on ARNA ROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Arena Pharmaceuticals is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth. In Arena Pharmaceuticals's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions. Q4 Earnings Recap Arena Pharmaceuticals reported Q4 earnings per share at $-2.1/share, which did not meet analyst predictions of $-1.85/share. See more from BenzingaClick here for options trades from Benzinga12 Health Care Stocks Moving In Wednesday's Pre-Market Session12 Health Care Stocks Moving In Tuesday's After-Market Session© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Arena Pharmaceuticals Reports Topline Results from Phase 2b CAPTIVATE Clinical Trial
    Business Wire

    Arena Pharmaceuticals Reports Topline Results from Phase 2b CAPTIVATE Clinical Trial

    Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced topline results from the randomized, double-blind, placebo-controlled Phase 2b CAPTIVATE clinical trial evaluating three doses of olorinab, a novel, oral, peripherally acting, highly selective, full agonist of the cannabinoid receptor 2 (CB2), in participants with abdominal pain due to Irritable Bowel Syndrome (IBS).